Study to Evaluate the Effects of Single Ascending Oral Doses of ACD856 on Safety, Tolerability and Pharmacokinetics

PHASE1CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

February 15, 2021

Primary Completion Date

February 22, 2022

Study Completion Date

February 22, 2022

Conditions
Alzheimer DiseaseCognition Disorder
Interventions
DRUG

ACD856

Single oral doses of ACD856 administered in a fasted state in escalation schedule of dose 1, dose 2, dose 3, dose 4, dose 5, dose 6 and dose 7. The escalation schedule may be adapted based on evaluation by internal Safety Review Committee.

DRUG

Placebo

Placebo oral solution

DRUG

ACD856 (fed cohort)

Single oral dose of ACD856 in fed state of either dose 4 or dose 5.

Trial Locations (1)

Unknown

Uppsala University Hospital, Uppsala

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AlzeCure Pharma

INDUSTRY

NCT05077631 - Study to Evaluate the Effects of Single Ascending Oral Doses of ACD856 on Safety, Tolerability and Pharmacokinetics | Biotech Hunter | Biotech Hunter